Merit Medical has acquired Solo Pace, Inc. for $45 million, integrating its precision intraprocedural pacing technologies into Merit's Cardiac Therapies platform. The acquisition is expected to be immaterial to Merit's 2026 financial results, suggesting a strategic rather than immediate financial impact.
Merit Medical has completed the acquisition of Solo Pace, Inc. for approximately $45 million, effective October 13, 2026. This move integrates Solo Pace's precision intraprocedural pacing technologies, previously distributed by Merit, into Merit's Cardiac Therapies platform. While the company states the acquisition will be immaterial to its 2026 financial results, it represents a strategic strengthening of Merit's product portfolio in the transcatheter heart valve procedures market. For traders, this is a long-term strategic play, potentially enhancing Merit's competitive position and future revenue streams, though short-term financial impact is minimal. The key opportunity lies in the potential for increased market share and synergy within its cardiac therapies division.